Maternal and Fetal Metabolic Changes

NCT ID: NCT06288126

Last Updated: 2024-03-01

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 457 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-08-01
• Study Completion Date: 2021-01-18

Brief Summary

The goal of this observational prospective project is to study the metabolic alterations during normal and complicated pregnancies, obtaining an early detection of metabolic changes, offering new insights into future prevention and treatment strategies for both mother and offspring.

Primary objectives:

• measurement of maternal blood adipokine levels, during the first trimester of pregnancy, in two groups of women (high and low risk), in order to identify early markers which, in conjunction with the medical history, can identify women at increased risk of developing GDM
• ultrasound measurement of adipose tissue deposits at ectopic sites, comparing low- and high-risk women, and assessing the effect of pregnancy on these deposits.
• Identification, by targeted ultrasound assessment, of fetuses at increased risk of macrosomia.

Secondary objectives:

• Evaluation of the prevalence of GDM and its complications in a population of low- and high-risk women.
• Evaluation of neonatal complications in children born to low- and high-risk mothers (need for resuscitation, hypoglycaemia, hypocalcaemia, admission to neonatal intensive care unit).

The participants will be recruited during first trimester ultrasound after signing the informed consent.

Detailed Description

Pregnancy has been defined "a stress test for life". During pregnancy, even if uncomplicated, women experience metabolic and cardiovascular changes that predispose to vascular endothelial dysfunction. Women who are already predisposed to this phenotype develop gestational hypertension or gestational diabetes (GDM), which can re-emerge later in life. This has been demonstrated by several studies in which the presence of pregnancy diseases (GDM, maternal preeclampsia and fetal growth disorder) correlate with the development of chronic disorders, such as chronic hypertension, diabetes mellitus and metabolic syndrome, suggesting a common pathogenic pathway. From this point of view, pregnancy constitutes a unique period to evaluate metabolic and cardiovascular markers, to better understand the pathogenesis of these disorders and possibly obtain preventive strategies. The identification of early biomarkers of metabolic dysfunction would be particularly useful in overweight and obese pregnant women. There is a growing prevalence of obesity worldwide; in developed Countries, 40-50% of the pregnant population is overweight and obese, which is, according to a recent report from the United Kingdom, the main contributing cause of death during gestation.

In addition, obesity and maternal hyperglycaemia during pregnancy may induce intrauterine overnutrition and fetal hyperinsulinemia, resulting in excessive fetal growth. Fetal macrosomia is associated with an increased risk of perinatal morbidity and mortality. Large babies have increased risk of intrapartum complications such as prolonged labour and shoulder dystocia. Moreover, the environmental and metabolic characteristics of intrauterine life deeply influence the individual in the long-term as a child and through adulthood, with possible adverse metabolic consequences, including predisposition to insulin resistance and obesity.

The evaluation of fetal tissue distribution and the recently introduced study of the fetal liver volume constitute very interesting markers of fetal adiposity and could be used as early indicators of insulin resistance in newborns.

The participants will be recruited during first trimester ultrasound after signing the informed consent. At 11-13 weeks:

• Ultrasound evaluation of fetal biometry and amniotic fluid will be performed. Periodic maternal anthropometric evaluation (weight gain and body mass index (BMI), blood pressure). Women will be divided in lean, overweight and obese.
• Blood sample for inflammatory cytokines will be taken.
• Maternal body composition evaluation through bioimpedance and/or highly reliable ultrasound-based analysis of ectopic fat. This approach is ideal to provide biomarkers of insulin resistance. In brief, women will be evaluated by a standardized set of US clips for the assessment of liver fat, cardiac fat, abdominal subcutaneous and visceral fat.

At 16-18 weeks: standard screening for gestational diabetes for high risk women, as for clinical practice

At 24-28 weeks:

• Standard screening for gestational diabetes to all women
• Fetal ultrasound to study fetal liver volume and/or subcutaneous fat tissue quantification. These constitute innovative techniques to obtain an early identification of macrosomic fetuses.

At delivery:

• Information on mode of delivery and any complications
• Within 48 hours of birth, anthropometric assessment of the infant according to clinical practice (weight, abdominal and head circumference).

Conditions

Pregnancy Related; Maternal-Fetal Relations; Metabolism Disorder, Glucose

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

High Risk Group

This group include women at high risk for gestational diabetes (GDM) according to most of the European guidelines. They have one or more of the following criteria: age ≥35 years, overweight or obesity, family history of diabetes, high-risk ethnicities, history of previous GDM or previous macrosomia, and high levels of fasting glycemia during the first trimester screening.

No interventions assigned to this group

Low Risk Group

This group will include women at low risk for GDM according to most of the European guidelines. They have none of the following criteria: age ≥35 years, overweight or obesity, family history of diabetes, high-risk ethnicities, history of previous GDM or previous macrosomia, and high levels of fasting glycemia during the first trimester screening.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• singleton pregnancy
• first visit between 11 and 14 weeks of pregnancy

Exclusion Criteria

• consent withdrawal
• multiple pregnancy
• prepregnancy diabetes mellitus
• women undergoing therapy with oral hypoglycaemic drugs
• previous bariatric surgery
• fetal chromosomal and/or major structural abnormalities were excluded

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Azienda Ospedaliero, Universitaria Pisana

OTHER

Sponsor Role: lead

Responsible Party

Tommaso Simoncini

Full Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Tommaso Simoncini, MD. PhD.

Role: PRINCIPAL_INVESTIGATOR

University of Pisa

Locations

Azienda Ospedaliera Universitaria Pisana

Pisa, , Italy

Countries

Italy

Other Identifiers

MoMM-FET

Identifier Type: -

Identifier Source: org_study_id